ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to treatment. Older women experience lower ADC treatment rates and longer delays ...
The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results